Brokerage : Daishin Securities
Analyst : Kahye Hong
Investment Rating : BUY (Maintained)
Target Price : KRW 410,000 (Upgraded)
Core Momentum : Inflow of recurring commercial milestones driven by expanding Keytruda Qlex adoption, complemented by platform extension into next-generation modalities like RNA and new licensing catalysts.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price KRW 410,000 (Upgraded by 6.6%) (Target price of KRW 409,505 derived via rNPV DCF methodology using WACC 7.37% and terminal growth rate of 4.5%, reflecting enterprise operating value of KRW 28.25 Trillion, net cash and financial assets of KRW 281.0 Billion, equity value of KRW 28.53 Trillion, and total shares of 69,631,000; upside potential of 34.4% based on the August 7, 2026 closing price of KRW 305,000)
- Market Data: KOSDAQ Index 798.81pt / Market Cap KRW 16.34 Trillion (Market Cap Weight 2.84%) / Capital Stock (Common) KRW 35.0 Billion / 52-Week High KRW 430,124, Low KRW 206,213 / 120-Day Average Trading Value KRW 156.4 Billion / Foreign Ownership 14.57% / Major Shareholders: Soonjae Park and 4 affiliates 20.33%, Inwoo Hyung and 2 affiliates 5.08%
- Annual Financial Forecast (Daishin Securities Estimates):
- 2026F: Revenue KRW 497.0 Billion (+270% YoY), SG&A KRW 140.0 Billion, Operating Profit KRW 301.0 Billion (Turned to black YoY, OPM 60.6%), Non-operating Profit KRW 95.0 Billion, Pre-tax Profit KRW 396.0 Billion, Net Profit (Controlling) KRW 314.0 Billion, EPS KRW 4,473, BPS KRW 10,649, PER 65.6x, PBR 28.6x, ROE 52.6%
- 2027F: Revenue KRW 512.0 Billion, SG&A KRW 145.0 Billion, Operating Profit KRW 308.0 Billion (OPM 60.2%), Non-operating Profit KRW 69.0 Billion, Pre-tax Profit KRW 377.0 Billion, Net Profit (Controlling) KRW 283.0 Billion, EPS KRW 4,030, BPS KRW 14,392, PER 72.8x, PBR 21.2x, ROE 32.2%
- 2028F: Revenue KRW 631.0 Billion, Operating Profit KRW 391.0 Billion (OPM 62.0%), Pre-tax Profit KRW 460.0 Billion, Net Profit (Controlling) KRW 345.0 Billion, EPS KRW 4,917, BPS KRW 19,026, PER 59.7x, PBR 16.0x, ROE 29.4%
🚀 2. [Market Opportunities & Business Outlook]
- Q2 2026 Financial Review & Milestone Recognition:
- Consolidated revenue reached KRW 68.9 Billion (+270% YoY) and operating profit came in at KRW 34.2 Billion (turning profitable YoY, OPM 49.6%).
- Out of KRW 63.3 Billion in total milestone/royalty revenues, sales milestones for Keytruda Qlex alongside development milestones from partners including Sanofi and AstraZeneca were recognized, signaling the onset of recurring commercial milestone inflows.
- Keytruda Qlex Adoption Acceleration in the US:
- According to Symphony Health data as of July 2026, Q2 Keytruda Qlex (SC) sales reached USD 463 Million (+262% QoQ), with its prescription share within US Keytruda treatments climbing to 10.6%.
- Commercial conversion has accelerated since the implementation of the permanent J-code in April 2026, tracking in line with Merck’s (MSD) initial SC transition roadmap.
- Solid financial trajectory is expected to continue in Q3, supported by recurring Keytruda Qlex sales milestones and upfront payments from the newly signed ALT-B4 agreement on August 5.
- Platform Enhancement & Next-Generation Modalities:
- The latest out-licensing agreement marks the expansion of the company’s subcutaneous (SC) delivery platform from traditional antibodies to novel biopharmaceutical drug classes.
- In parallel with global peer Halozyme extending its ENHANZE platform from ADCs to nucleic acid therapeutics, Alteogen is actively pursuing platform applications in RNA therapeutics, providing medium-to-long-term valuation support.
📝 Editor’s Comment (Perspective)
The analyst views Alteogen as a biopharmaceutical company securing cash-flow stability through recurring commercial milestones from Keytruda SC (Qlex) market penetration, while unlocking structural platform re-rating by expanding its subcutaneous delivery technology beyond antibodies into new modalities like RNA. The overarching perspective prioritizes the accelerating commercial conversion rate of Qlex following J-code assignment and the pipeline expansion driven by new biopharmaceutical licensing deals, rather than quarterly earnings volatility related to technical milestone recognition timings.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the continued expansion of Keytruda Qlex prescription share via US Symphony Health tracking, the scale of quarterly commercial milestone inflows starting from Q3 2026, and the formal execution of additional platform licensing agreements targeting RNA and next-generation modalities. These developments can be verified through future quarterly earnings releases, official company IR presentations, and regulatory filings on DART/KRX.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
